Vetcontact
Bayer Novartis Boehringer-Ingelheim Virbac France
Vetcontact Events Presentations Posters Case Studies Speciality Organisations
CPD Forum Products Login/Newsletter
Oncology Home ONCOLOGY
CUTANEOUS AND MUCOCUTANEOUS PLASMACYTOMAS IN DOGS
These tumours are not too common but can be very fascinating. This excellent study gives a lot of new insights: Wchich breeds are overrepresented, which localisations are the most common etc. etc. Very interesting and useful for the daily practice.

In this study the clinico-pathological aspects of cutaneous and mucocutaneous plasmacytomas were investigated in 63 dogs (one dog with two tumours).

The tumours were most commonly observed in the skin of the trunk and legs.

Yorkshire Terrier (n = 8) was the most commonly affected breed and males were affected more commonly than females (36 versus 23, respectively).

Plasmacytomas were histologically classified into mature, hyaline, cleaved, asynchronous, monomorphous blastic and polymorphous blastic cell types.

Monomorphous blastic cell type was the most frequent type (n = 21), followed by cleaved (n = 19) and asynchronous (n = 11) cell types. Secondary amyloid depositions were observed in eight cases.

Immunohistochemical staining showed monoclonal lambda light chain positivity in all cases. In the immunohistochemical staining for cyclin D1, which is a prognostic marker in human plasma cell tumours, moderate numbers of positive tumour cells were observed in only one case of (muco)cutaneous plasmacytoma.

All other cases were negative or contained few positive tumour cells.

On the other hand, high numbers of tumorous plasma cells reacted positively with cyclin D1 in three out of six cases of canine multiple myelomas.

Prognosis of the (muco)cutaneous plasmacytomas was good, except in one dog which developed a lymphoma afterwards.

No significant correlations were observed between the cell type and the location of the tumour, presence of amyloid or prognosis.


Source: Cangul IT, Wijnen M, Van Garderen E, van den Ingh TS. (2002): Clinico-pathological aspects of canine cutaneous and mucocutaneous plasmacytomas. In: J Vet Med A Physiol Pathol Clin Med. 2002 Aug;49(6):307-12.


Tell a friend   |   Print version   |   Send this article

Toceranib phosphate (Palladia®) in canine gastrointestinal stromal tumors Gastrointestinal stromal tumors (GISTs) are uncommon intestinal neoplasms in the dog. Literature regarding adjunctive therapy for GISTs in dogs is sparse. Highâ€risk GISTs in humans respond to tyrosine kinase inhibition in the adjuvant setting. This recently online published study reviews cases of toceranib phosphate use in dogs with GISTs and provides initial assessment of possible biological activity. A secondary aim was to evaluate patient and tumor characteristics for possible prognostic value.

  • Hypoechoic tissue changes in dogs with malignant prostatic lymphoma
  • Novel intratumoral therapy in canine transmissible venereal tumour
  • ACVIM small animal consensus statement on safe use of cytotoxic chemotherapeutics
  • Extracellular vesicles in mammary cancer of dogs and cats
  • Non-tuberculous Mycobacteria in healthy slaughtered cattle and the abattoir
  • Canine mammary tumours as model for hereditary breast cancer susceptibility genes in humans
  • Malignant anal sac melanoma in dogs
  • Carboplatin sustained-release delivery system in dogs with cancer
  • Novel radiation therapy for inoperable massive hepatocellular carcinoma
  • Red blood cell storage lesion - an update
  • Canine osteosarcoma cells and aurora kinase inhibitors
  • Exocrine pancreatic neoplasias in cats - the most common signs
  • Radiation therapy of oral melanomas in cats
  • Successful treatment of persistent oral papillomatosis with a recombinant oral vaccine
  • Photodynamic therapy in equine periocular squamous cell carcinoma
  • Masitinib in canine mast cell tumors
  • Latent viral phase in horses with sarcoids?
  • Calcified tumours of the paranasal sinuses in horses
  • Canine cerebellar leptomeningeal carcinomatosis (case report)
  • Canine Cutaneous Perivascular Wall Tumors
  • Reconstruction of the lower eyelid in cats with squamous cell carcinoma
  • Transposition of first digital pad for reconstruction of a soft tissue defect (case report)
  • Connexins 26 and 43 in canine hyperplastic and neoplastic mammary glands
  • Advances in mast cell tumour diagnosis and therapy
  • Survival time in dogs with non-treated nasal carcinomas
  • Paraneoplastic alopecia associated with liver carcinoma in a cat (case report)
  • Are mast cell tumors in the groin or perineal region more aggressive than elsewhere?
  • Mitotic index and the survival time in canine cutaneous mast cell tumors
  • Stromal tumors in the gastrointestinal tract of equids
  • Osteosarcoma in horses
  • Maropitant in the treatment of cisplatin-induced emesis in dogs
  • Reevaluation of the 2-Year Protocol for Treating Canine Lymphosarcoma
  • Malignant ameloblastic fibro-odontoma in a Collie (case report)
  • Epithelioid variant of hemangioma and hemangiosarcoma in various species
  • New canine osteosarcoma cell line
  • Chemotherapy plus half-body radiation therapy for canine lymphoma
  • Recurrence rate of surgically excised grade II mast cell-tumors
  • Intestinal T-cell lymphoma in dogs
  • Prognostic factors in multiple cutaneous mast cell tumours
  • Bilateral salivary adenocarcinoma with multiple metastases in a cat
  • Lineage differentiation of canine lymphoma/leukemias
  • Partial esophagectomy in esophageal sarcomas in dogs
  • Surgery alone or surgery plus chemotherapy in feline injection-site lymphosarcomas?
  • Biphasic synovial sarcoma in a young dog: pathologic features
  • Canine Hemophagocytic Histiocytic Sarcoma
  • Mast cells and angiogenesis in canine melanomas - prognostic factors
  • No higher incidence of diseases in rescue dogs from September 9th
  • Conjunctival hemangioma and hemangiosarcoma in the dog
  • Uveal metastasis of a primary pulmonary adenocarcinoma
  • Vascular hamartoma in a horse
  • Correlation of CT-MRI and histopathology in dogs with brain neoplasms
  • Indolent Nodular Lymphoma in Dogs
  • Pugs and mast cell tumours
  • Cerebellar myxoid type meningioma in a dog
  • Carboplatin in canine tonsillar squamous cell carcinoma
  • Partial foot amputation in dogs
  • Mast cells and angiogenesis in canine melanomas
  • Immunhistochemistry in canine unidentified round cell tumors
  • First gastric carcinoid in a cat
  • Thyroid carcinoma in dogs - is surgical resection sufficient?
  • Vaccine-induced rhabdomyosarcoma in a cat
  • Gastric adenocarcinomas and leiomyosarcomas
  • Colorectal plasmocytomas - how do they behave?
  • ACTH tests in dogs with different neoplasia
  • Collie eye anomaly in a non-Collie breed
  • How does the immune system recognize and respond to cancer?
  • Gemcitabine as radiosensitizer for nonresectable oral SCC in cats
  • Multicentric intravascular lymphoma in the nervous system of a dog (case report)
  • Ectopic secretion of GHRH
  • MRI in the differentiation between neoplastic and non-neoplastic brain lesions
  • Acromegaly in cats
  • Glioblastoma multiforme in dogs
  • Malignant craniopharyngioma in two cats: histopathological findings
  • Skin myxoma in a dog (case report)
  • Acute granulocytic ehrlichiosis in a dog (case report)
  • Skin metastases of a bronchial adenocarcinoma in a cat (case report)
  • Osteosarcoma 11 years after TPO
  • Malignant B-cell lymphoma of the Harder`s gland in a rabbit (case report)
  • Mixed pancreatic acinar-endocrine carcinoma in a dog (case report)
  • Successful stem-cell transplantation in a dog with cancer
  • Carboplatin and piroxicam in transitional cell carcinoma of the bladder
  • Hypercalcemia caused by oral neoplasia
  • One or two doses of cisplatin in canine osteosarcoma?
  • Monoclonal gammopathies in dogs: the most common reasons
  • Ureteral obstruction due to mast cell tumor
  • Intestinal Mucinous Adenocarcinoma in a Dog (case report)
  • Heat shock proteins expression in canine skin tumors
  • Piroxicam and carboplatin in canine oral non-tonsillar squamous cell carcinoma
  • Hepatobiliary neuroendocrine carcinoma in cats
  • Colorado State University receives 1 million dollars for cancer biology program
  • Total Skin Electron Beam Irradiation In Canine Mykosis Fungoides
  • Cancer is the leading cause of death in dogs and cats
  • New FDA report on Acrylamide
  • Do eczema drugs increase the risk of cancer?
  • Piroxicam in transitional cell carcinoma of the canine bladder
  • Retrobulbar malignant fibrous histiocytoma in a dog
  • Surgical therapy of scapular osteosarcomas
  • Cox-2-expression in canine keratinocytes
  • Surgical therapy in cats with middle ear tumours with brainstem extension
  • Partial or complete foot amputation in dogs?
  • Four Fraction Palliative Radiotherapy for Canine Osteosarcoma
  • No health problems in search and rescue dogs from September 11,2001
  • Emphysematous prostatitis in a dog
  • Telomerase-targeted therapies in canine cancer cell lines
  • Promising therapy of canine haemangiosarcoma with suberoylanilide hydroxamic acid
  • The pre-surgical work-up of tumor patients
  • Sonographic characteristics of abdominal histiocytic neoplasms in dogs
  • Non-coherent light - a good alternative in treatment of superficial tumours?
  • Prednisolone plus radiotherapy for canine mast cell tumours
  • Intercalary Bone Grafts for Joint and Limb Preservation in dogs with malignant bone tumors
  • Is radiotherapy in cutaneous grade II mast cell tumors mandatory?
  • Chronic recurrent cystitis or transitional cell carcinoma - the differentiation
  • Conjunctival B-cell lymphoma in a cat
  • Intravascular lymphoma in a dog (case report)
  • Primary intratracheal lymphosarcoma in cats
  • Iridium brachytherapy plus surgery in canine mast cell tumors
  • Pancreatic adenocarcinomas in cats
  • Carmustine instead of cyclophosphamide in canine lymphoma
  • Transitional cell carcinoma in dogs - update in diagnosis and therapy
  • Pericardial effusion - cave lymphosarcoma



  • [ Home ] [ About ] [ Contact / Request ] [ Privacy Policy ]

    Copyright © 2001-2018 VetContact GmbH
    All rights reserved